Product Data Sheet

CDK7-IN-26

Molecular Weight: 468.49
Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC $_{50}$: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC $_{50}$ of 0.15 μ M $^{[1]}$.
IC ₅₀ & Target	IC50: 7.4 nM (CDK7) ^[1]

REFERENCES

[1]. Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA